,outcome,arm 1,arm 2
0,intervention,,
0,"incidence of adverse events, total study group","11.3, 17.9, 19.0 %, 25.2, 3.2 %, 32.5 %, 37.3, leukopenia (, noninduction ,","11.3, 17.9, 19.0 %, 25.2, 3.2 %, 32.5 %, 37.3, leukopenia (, noninduction ,"
0,"incidence of adverse events, cytomegalovirus ( CMV ) infection, total study group","10.1 % ,, 5.7 % ,, 9.5 %","10.1 % ,, 5.7 % ,, 9.5 %"
